Metastatic cancer

Common Name(s)

Metastatic cancer

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Metastatic cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Metastatic cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Metastatic cancer" returned 4531 free, full-text research articles on human participants. First 3 results:

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
 

Author(s): Andrea Sartore-Bianchi, Elena Ardini, Roberta Bosotti, Alessio Amatu, Emanuele Valtorta, Alessio Somaschini, Laura Raddrizzani, Laura Palmeri, Patrizia Banfi, Erica Bonazzina, Sandra Misale, Giovanna Marrapese, Antonella Leone, Rachele Alzani, David Luo, Zachary Hornby, Jonathan Lim, Silvio Veronese, Angelo Vanzulli, Alberto Bardelli, Marcella Martignoni, Cristina Davite, Arturo Galvani, Antonella Isacchi, Salvatore Siena

Journal:

 

In metastatic colorectal cancer (CRC), actionable genetic lesions represent potential clinical opportunities. NTRK1, 2, and 3 gene rearrangements encode oncogenic fusions of the tropomyosin-receptor kinase (TRK) family of receptor tyrosine kinases in different tumor types. The TPM3-NTRK1 ...

Last Updated: 13 Nov 2015

Go To URL
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
 

Author(s): Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu, Gunther Boysen, Nuria Porta, Penny Flohr, Alexa Gillman, Ines Figueiredo, Claire Paulding, George Seed, Suneil Jain, Christy Ralph, Andrew Protheroe, Syed Hussain, Robert Jones, Tony Elliott, Ursula McGovern, Diletta Bianchini, Jane Goodall, Zafeiris Zafeiriou, Chris T Williamson, Roberta Ferraldeschi, Ruth Riisnaes, Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi-Mi Wu, Xuhong Cao, Rachel Brough, Helen Pemberton, Roger A'Hern, Amanda Swain, Lakshmi P Kunju, Rosalind Eeles, Gerhardt Attard, Christopher J Lord, Alan Ashworth, Mark A Rubin, Karen E Knudsen, Felix Y Feng, Arul M Chinnaiyan, Emma Hall, Johann S de Bono

Journal: N. Engl. J. Med.. 2015 Oct;373(18):1697-708.

 

Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) ...

Last Updated: 29 Oct 2015

Go To URL
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
 

Author(s): H Gilbert Welch, David H Gorski, Peter C Albertsen

Journal: N. Engl. J. Med.. 2015 Oct;373(18):1685-7.

 

Last Updated: 29 Oct 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Metastatic cancer" returned 442 free, full-text review articles on human participants. First 3 results:

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
 

Author(s): J Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, Axel Grothey, Scott Kopetz, Alan Rong, Kelly S Oliner, Roger Sidhu

Journal: Cancer Treat. Rev.. 2015 Sep;41(8):653-9.

 

RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. ...

Last Updated: 22 Aug 2015

Go To URL
Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.
 

Author(s): Brian Lewis, Elie Chalhoub, Carla Chalouhy, Oliver Sartor

Journal: Oncology (Williston Park, N.Y.). 2015 Jul;29(7):483-8.

 

Ra-223 (radium-223) is an alpha particle-emitting radiopharmaceutical with targeted uptake in areas of osteoblastic lesions. The combination of targeted skeletal uptake, short tissue-penetration range, and high energy of alpha particles allows for targeted cell killing and a low toxicity ...

Last Updated: 16 Jul 2015

Go To URL
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
 

Author(s): Julie N Graff, Tomasz M Beer

Journal: Oncology (Williston Park, N.Y.). 2015 Jun;29(6):416-23.

 

Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety ...

Last Updated: 20 Jun 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
 

Status: Recruiting

Condition Summary: Metastatic Cancer; Pancreatic Cancer; Mesothelioma; Ovarian

 

Last Updated: 3 Nov 2015

Go to URL

Last Updated: 14 Oct 2015

Go to URL
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
 

Status: Recruiting

Condition Summary: Metastatic Cancer; Metastatic Melanoma

 

Last Updated: 31 Dec 2015

Go to URL